Your own tumor cells could be the key to fighting cancer

NCT ID NCT05417750

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is safe and can shrink tumors. The study included 43 patients with cancers like melanoma, cervical cancer, and lung cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tumor-infiltrating lymphocytes (TIL) plus sintilimab
What this could lead to
If successful, this could point toward a new immunotherapy option for people with advanced solid tumors like melanoma or cervical cancer.
What could go wrong
This is a very early phase 1 trial with only 43 participants, so safety and effectiveness are not yet proven. The treatment involves a complex process and may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, 100039, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.